<H1>Chapter DOI: 10.1007/s00105-015-3680-3<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>7</td></tr><tr><td>Springer references</td><td>0</td></tr><tr><td>Non Springer references</td><td>7</td></tr><tr><td>BibStructured Count</td><td width="10%">5</td></tr><tr><td>BibUnstructured Count</td><td width="10%">2</td></tr><tr><td>DOI already available in SpringerLink</td><td>5</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Bellodi S, Shah KN (2015) Biologic response modifiers and pediatric psoriasis. Pediatr Dermatol 32(3):303&#8211;320</td><td><a href=http://dx.doi.org/10.1111/pde.12547>10.1111/pde.12547</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>European Medicines Agency </span> (<span style='background:#66FF66'>2015</span>) <span style='background:#FFD9B3'>Zusammenfassung des Europ&#228;ischen &#214;ffentlichen Beurteilungsberichts (EPAR) f&#252;r Humira</span> . EMA/178267/2015, EMEA/H/C/000481</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3</td><td>BibUnstructured</td><td>Fachinformation &lt;Superscript&gt;Enbrel&#174;&lt;/Superscript&gt; 10 mg/25 mg/50 mg</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Hawrot AC, Metry DW, Theos AJ, Levy ML (2006) Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol 23(1):67&#8211;71</td><td><a href=http://dx.doi.org/10.1111/j.1525-1470.2006.00174.x>10.1111/j.1525-1470.2006.00174.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A, Etanercept Pediatric Psoriasis Study Group (2008) Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 358(3):241&#8211;251</td><td><a href=http://dx.doi.org/10.1056/NEJMoa066886>10.1056/NEJMoa066886</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Paller AS, Siegfried EC, Eichenfield LF, Pariser D, Langley RG, Creamer K, Kricorian G (2010) Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol 63(5):762&#8211;768</td><td><a href=http://dx.doi.org/10.1016/j.jaad.2010.04.004>10.1016/j.jaad.2010.04.004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Raychaudhuri SP, Gross J (2000) A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol 17(3):174&#8211;178</td><td><a href=http://dx.doi.org/10.1046/j.1525-1470.2000.01746.x>10.1046/j.1525-1470.2000.01746.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>